Reactions 1871, p200 - 4 Sep 2021

(1)

Reactions 1871, p200 - 4 Sep 2021

Hydroxychloroquine/mycophenolate mofetil/prednisone

S SARS-CoV-2 infection: case report

In a descriptive, observational, cross-sectional study involving 28 patients who responded to a survey from 15 April 2020 to 15 May 2020, a 50-year-old woman was described who developed SARS-CoV-2 infection following immunosuppressive therapy with hydroxychloroquine, mycophenolate mofetil and prednisone for uveitis associated with sarcoidosis [routes, duration of treatments to reaction onset and outcome not stated; not all dosages stated].

The woman, who had uveitis associated with sarcoidosis, was receiving immunosuppressive therapy with hydroxychloroquine 100 mg/day, prednisone 20 mg/day and mycophenolate mofetil. Subsequently, she was hospitalised with fever, cough, anosmia, dyspnoea, dysgeusia, diarrhoea and asthenia. Her nasopharyengeal swab was found to be positive for SARS-CoV-2 infection on RT- PCR. Her immunosuppressive therapy with hydroxychloroquine, mycophenolate mofetil and prednisone was suspected to have contributed in the development of SARS-CoV-2 infection.

Fanlo P, et al. Impact of novel coronavirus infection in patients with uveitis associated with an autoimmune disease: result of the COVID-19-GEAS patient survey. Archivos de la Sociedad Espanola de Oftalmologia 96: 347-352, No. 7, Jul 2021. Available from: URL: http://doi.org/10.1016/j.oftal.2020.12.011 803592797